{
  "ptid_time": "041_S_4143_2011-07-28",
  "img_path": "/data/qiuhui/data/adni/images/041_S_4143/2011-07-28/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 41,644 mm³, 86.4% above the reference mean. With a Z-score of 2.16 (98.5th percentile), this represents significant enlargement; hippocampal volume measures 5,637 mm³, 26.6% below the reference mean. With a Z-score of -2.99 (0.1th percentile), this represents significant atrophy; whole brain volume measures 945,306 mm³, 8.1% below the reference mean. With a Z-score of -1.01 (15.5th percentile), this represents mild atrophy; entorhinal cortex volume measures 1,999 mm³, 48.7% below the reference mean. With a Z-score of -3.77 (0.0th percentile), this represents profound atrophy; fusiform gyrus volume measures 16,429 mm³, 9.8% below the reference mean. With a Z-score of -1.10 (13.5th percentile), this represents mild atrophy; middle temporal gyrus volume measures 18,681 mm³, 9.0% below the reference mean. With a Z-score of -0.80 (21.3th percentile), this represents normal volume . ",
  "text_data": "Age is 63.6 years. Gender is Female. Education: 19 years. Handedness: Left. Race: White. Medical history: Head, Eyes, Ears, Nose and Throat; Cardiovascular; Endocrine-Metabolic; Gastrointestinal; Hematopoietic-Lymphatic; Allergies or Drug Sensitivities; Major Surgical Procedures. MMSE: 29.0. MoCA: 23.0. Logical Memory: 9.0. Laboratory findings: Monocytes: 10.50 (significant elevated); Lymphocytes: 0.65 (significant reduced); Total Bilirubin: 0.80 (significant elevated); GGT: 49.00 (profound elevated). APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 1.03 SUVR (normal ); Total tau: 243.10 pg/mL (normal ); Phosphorylated tau: 20.79 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant hippocampal and entorhinal cortex atrophy, which are hallmark features of Alzheimer's disease (AD), alongside ventricular enlargement suggestive of neurodegeneration. However, cognitive scores (MMSE 29, MoCA 23) are borderline for MCI (MoCA <26 suggests possible impairment), and biomarkers (normal tau, amyloid) do not support AD pathology.  \n**Diagnosis:** **MCI** (due to cognitive decline and structural atrophy, but biomarker profile is atypical for AD).  \n**Confidence:** **Medium** (conflicting evidence: imaging strongly suggests neurodegeneration, but biomarkers and high MMSE are less typical for AD).  \n\n**Note:** Further clinical correlation (e.g., longitudinal cognitive testing, FDG-PET, or CSF Aβ42) would strengthen confidence. Non-AD etiologies (e.g., hippocampal sclerosis, primary age-related tauopathy) could also explain this pattern.",
  "timestamp": "2025-07-26T07:13:29.706185"
}